After disease onset with MM manifestation, the further clonal evolution of malignant plasma cell subsets is driven by late stage (or secondary) somatic mutations involving KRAS, NRAS, BRAF, TP53, and DIS3 that are among the most frequent mutated genes in MM. This evidence concerns the gene KRAS and Miyoshi myopathy.